Mosliciguat is an investigational soluble guanylate cyclase (sGC) activator for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Rather than stimulating native soluble guanylate cyclase the way sGC stimulators do, mosliciguat directly activates the heme-free, nitric-oxide-unresponsive form of the enzyme, the form that accumulates in damaged, oxidized tissue. PH-ILD lungs may be precisely the environment where that form predominates, making the drug potentially relevant where other sGC-targeting agents cannot act. Its mechanism differs from prostacyclin-pathway therapy such as inhaled treprostinil (Tyvaso).
Pulmonary hypertension associated with interstitial lung disease (PH-ILD)
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
